Susquehanna International Group, LLP Genprex, Inc. Call Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$1.0 - $58.8 $9,200 - $540,960	-9,200 Reduced 20.72%	35,200 $51,000
Q3 2022 Nov 14, 2022	SELL	$1.32 - $58.0 $114,312 - $5.02 Million	-86,600 Reduced 66.11%	44,400 $63,000
Q2 2022 Aug 15, 2022	SELL	$1.28 - $2.31 $119,552 - $215,754	-93,400 Reduced 41.62%	131,000 $182,000
Q1 2022 May 16, 2022	BUY	$1.82 - $3.5 $354,900 - $682,500	195,000 Added 663.27%	224,400 $507,000
Q2 2021 Aug 11, 2021	SELL	$3.11 - $4.87 $45,095 - $70,615	-14,500 Reduced 33.03%	29,400 $98,000
Q1 2021 May 17, 2021	SELL	$3.66 - $7.67 $719,922 - $1.51 Million	-196,700 Reduced 81.75%	43,900 $189,000
Q4 2020 Feb 16, 2021	BUY	$3.03 - $5.51 $451,167 - $820,439	148,900 Added 162.38%	240,600 $998,000
Q3 2020 Nov 16, 2020	BUY	$2.9 - $4.29 $134,270 - $198,627	46,300 Added 101.98%	91,700 $308,000
Q1 2020 May 15, 2020	BUY	$0.28 - $6.23 $12,712 - $282,842	45,400 New	45,400 $110,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $64.3M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.